Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule to Healthy Adults
Latest Information Update: 04 Jul 2023
At a glance
- Drugs TDENV LAV (Primary)
- Indications Dengue
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK
- 06 Apr 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 25 Nov 2005 New trial record.